Spectrum Pharmaceuticals, Inc. Makes Decision To Advance SPI-2012, A Novel Long-Acting GCSF, To Phase 3 Due To Positive Phase 2 Results In Its Collaboration Program With Hanmi Pharmaceutical, Co., Ltd

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced the Phase 3 Go/No-Go decision for SPI-2012, its long acting Granulocyte Stimulating Factor (GCSF), and is planning for the start of Phase 3 clinical trials next year.

Help employers find you! Check out all the jobs and post your resume.